SCHEMBL17653148

SCHEMBL17653148

COc1nc(CCC(C)C)nc2ccc(C=O)cc12

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AAK1 Q2M2I8 3/20 0.40
MAPK1 P28482 1/20 0.36
ALDH1A1 P00352 8/20 0.35
TSHR P16473 1/20 0.35
PTGER4 P35408 1/20 0.34
FDPS P14324 1/20 0.34
KDM4E B2RXH2 3/20 0.33
MAPT P10636 2/20 0.33
MEN1 O00255 2/20 0.33
NPC1 O15118 2/20 0.33
POLB P06746 2/20 0.33
KMT2A Q03164 2/20 0.33
HSD17B10 Q99714 1/20 0.33
HPGD P15428 2/20 0.33
AOX1 Q06278 1/20 0.33
TRIM24 O15164 1/20 0.33
ALDH5A1 P51649 1/20 0.33
ABAT P80404 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
TRIM33 Q9UPN9 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17653224 0.88 AAK1 (0.40) AAK1MAPK1ALDH1A1KDM4EMAPT
SCHEMBL17653336 0.81 AAK1 (0.43) AAK1MAPK1ALDH1A1KDM4EMAPT
SCHEMBL17653085 0.80 AAK1 (0.43) AAK1ALDH1A1KDM4EMAPTMEN1
SCHEMBL17653260 0.80 PDE10A (0.41) AAK1ALDH1A1KDM4EMAPTMEN1
SCHEMBL17653201 0.80 AAK1 (0.40) AAK1ALDH1A1KDM4EMAPTMEN1
SCHEMBL17653207 0.77 AAK1 (0.69) AAK1MAPT
SCHEMBL17653248 0.74 AAK1 (0.47) AAK1
SCHEMBL17653102 0.72 AAK1 (0.65) AAK1
SCHEMBL17653153 0.71 TUBB4A (0.44) AAK1MAPK1ALDH1A1KDM4EKMT2A
SCHEMBL17653171 0.69 ALDH1A1 (0.39) AAK1ALDH1A1TSHRKDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170239249-A1 QUINAZOLINE-BASED KINASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2017-08-24 US disclosed
US-20170239249-A1 QUINAZOLINE-BASED KINASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2017-08-24 US disclosed
US-20170239249-A1 QUINAZOLINE-BASED KINASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2017-08-24 US disclosed
EP-3200797-A1 QUINAZOLINE-BASED KINASE INHIBITORS Bristol-Myers Squibb Company (US) 2017-08-09 EP disclosed
WO-2016053794-A1 QUINAZOLINE-BASED KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2016-04-07 WO disclosed
WO-2016053794-A1 QUINAZOLINE-BASED KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2016-04-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170239249-A1 QUINAZOLINE-BASED KINASE INHIBITORS AAK1, ULK1, NCK1 AAK1 1/4885MAPK1 387/4885ALDH1A1 3926/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.